Immunostaining characteristics of irisin in benign and malignant renal cancers

Kuloğlu, Tuncay; Artaş, Gökhan; Yardım, Meltem; Şahin, İ̇brahim; Aydin, Y.; Beyoğlu, N; Ozercan, I H; Yalçın, Mehmet Hanifi; Uğur, Kader; Aydın, Süleyman

doi:10.1080/10520295.2019.1586998

Cited by 20 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irisin is produced by the proteolytic cleavage of the fibronectin type III domain-containing protein 5 (FNDC5) ( Bostrom et al, 2012 ) and plays a pivotal role in the occurrence and development of obesity, diabetes, non-alcoholic fatty liver disease, and other metabolic diseases ( Arias-Loste et al, 2014 ; Shelbaya et al, 2017 ; Suk et al, 2018 ). However, recent studies conducted by Kuloglu et al (2016) demonstrated that irisin immunoreactivity was significantly increased in human breast cancer tissues compared with that in healthy breast tissues, indicating that irisin may also play a critical role during carcinogenesis. Moreover, Provatopoulou et al (2015) found that the serum levels of irisin in breast cancer patients were significantly reduced compared with those in healthy controls, and one unit increase in irisin levels resulted in an approximately 90% reduction in the probability of breast cancer.…”

Section: Introductionmentioning

confidence: 97%

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

et al. 2018

View full text Add to dashboard Cite

Objectives: To explore the activating transcription factor 3 (ATF3) and fibronectin type III domain-containing protein 5 (FNDC5)/irisin protein levels in serum and mRNA levels in subcutaneous and visceral white adipose tissue (sWAT and vWAT) in normal-weight (NW) and overweight/obese (OW/OB) patients with colorectal cancer (CRC).Methods: 76 CRC patients and 40 healthy controls were recruited. Serum ATF3 and irisin levels were detected by using ELISA kits, and the mRNA expression levels in sWAT and vWAT were measured by performing RT-qPCR.Results: The serum ATF3 levels were greater by 37.2%, whereas the irisin levels were lower by 23.3% in NW+CRC patients compared with those in healthy controls. CRC was independently associated with both ATF3 and irisin levels. The probability of CRC greater by 22.3-fold in individuals with high ATF3 levels compared with those with low ATF3 levels, whereas the risk of CRC in subjects with high irisin levels was lower by 78.0% compared to the risk in those with low irisin levels after adjustment for age, gender, BMI, and other biochemical parameters. Serum ATF3 and irisin could differentiate CRC patients from controls with receiver operating characteristic (ROC) curve areas of 0.745 (95% CI, 0.655–0.823) and 0.656 (95% CI, 0.561–0.743), respectively. The combination of ATF3 and irisin exhibited improved diagnosis value accuracy with ROC curve areas of 0.796 (95% CI, 0.710–0.866) as well as 72.6% sensitivity and 80.0% specificity.Conclusion: Increased ATF3 and reduced irisin levels were observed in sera from CRC patients. Individuals with high ATF3 and low irisin levels were more likely to have CRC. ATF3 and irisin represent potential diagnostic biomarkers for CRC patients.

show abstract

Section: Introductionmentioning

confidence: 97%

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

et al. 2018

View full text Add to dashboard Cite

show abstract

“…16 Based on this result, they concluded that the notable escalation of irisin immunoreactivity in several tissues procured from breast, ovary, and cervix carcinomas, and endometrial hyperplasia played a significant role during carcinogenesis. 16 The presumable relationship between irisin and breast cancer was suggested by proving distinguished serum irisin levels of breast cancer patients compared with those of control. 22 More clearly, the level of serum irisin in patients with breast cancer was considerably lower than in normal subjects; irisin levels could, therefore, be used as a diagnostic key marker in breast cancer.…”

Section: Irisin Concentration As a Biomarker Of Tumor Burdenmentioning

confidence: 96%

“…24 A contemporary study revealed that upsurge trend of irisin immunoreactivity in tissues obtained from ovary, cervix, breast cancer, and endometrial hyperplasia indicated an important role of irisin during carcinogenesis. 16 Other studies demonstrated that irisin significantly reduced cell number, viability, and migration of malignant breast cancer cells (MDA-MB-231), 23 HCC (HepG2 and SMCC7721), 27 and pancreatic cancer cell (MIA PaCa-2 and Panc03.27). 29 Likewise, irisin reduced invasion of lung cancer cells (A549 and NCI-H446).…”

Section: Role Of Irisin In Tissue Invasion and Metastasismentioning

confidence: 97%

“…A recent study has disseminated that an increased immunoreactivity of irisin in several cancerous tissues has a crucial role in cancer development. 16 Gannon et al 23 have shown that irisin significantly increases the cytotoxic effect of doxorubicin (Dox) in malignant breast cancer cells without causing any side effects to nonmalignant cells. Shao et al 26 reported that A549 and NCI-H446 cells treated with irisin can elevate the expression of E-cadherin, and reduce N-cadherin and vimentin, indicating that EMT may be inhibited by irisin treatment.…”

Section: Multifunctional Effects Of Irisin In Cancer Cellsmentioning

confidence: 99%

“…Although irisin was initially identified in skeletal muscle and adipose tissue, 11 it has also been identified in the brain, pancreas, liver, stomach, 12 heart, 13 spleen, and skin. 14 Besides, recent studies revealed that irisin expression is increased in metabolic disorder patients, 15 cervical cancer, endometrial cancer, 16 cancer cachexia, 17 and prior gestational diabetes mellitus. 18 Conversely, expression of irisin is reduced in patients with type 2 diabetes 19,20 and non-alcoholic fatty liver disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pathophysiological role of endogenous irisin against tumorigenesis and metastasis: Is it a potential biomarker and therapeutic?

et al. 2019

View full text Add to dashboard Cite

In the last few decades, there has been notable progress in understanding the molecular and cellular basis of the complex process involved in cancer. In this context, tumor-promoting inflammation, dysregulation of apoptotic signaling, tissue invasion and metastasis, and cancer microenvironment have recently attracted interest from researchers. Irisin is a hormone released by muscles during exercise and it directly acts on key functional cells involving energy metabolism and homeostasis. Recently, many studies have reported the anticancer effect of irisin against different types of cancer. Translation of these findings to clinical practice for the diagnosis and treatment of several types of cancer is urgently required. In this review, we summarized preclinical and clinical studies on the anticancer effects of irisin in various types of cancer, and also discussed the mechanisms activated by irisin to suppress cancer pathogenesis. We further discussed the serum level of irisin related to different types of cancer to understand more clearly the association between irisin concentration and tumor burden. This review may serve as a solid foundation for researchers and physicians to support basic and clinical studies on irisin as a promising strategy for early diagnosis and treatment of a various types of cancers.

show abstract

The Effect of Irisin on Proliferation, Apoptosis, and Expression of Metastasis Markers in Prostate Cancer Cell Lines

et al. 2022

View full text Add to dashboard Cite

Introduction Irisin is a newly discovered myokine released from skeletal muscle during exercise. The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that play a key role in the metastatic process via degrading extracellular matrix. The aim of this study was to investigate the effect of irisin on expression of metastatic markers MMP2 and MMP9 and induced apoptosis in human prostate cancer cells. Methods In this study, we examined the effect of different concentrations of irisin on induced apoptosis and cell viability of two cell lines, LNCaP and DU-145, by using flow cytometry and MTT assay, respectively. The expression of MMP2 and MMP9 genes was also analyzed by real-time PCR after irisin treatment. Data were analyzed using the comparative cycle threshold 2 −∆∆Ct method. Results Cell viability was reduced in both LNCaP and DU-145 cell lines at different concentrations of irisin. However, this decreased cell viability was strongly significant ( p < 0.05) only at 5 and 10 nM concentrations of irisin in the LNCaP cell line. Furthermore, irisin could induce apoptosis in both cell lines at a concentration of 10 nM compared to 5 nM. Real-time PCR results also demonstrated a decreased expression in MMP2 and MMP9 genes in a concentration-dependent manner in both cell lines. Conclusion These results showed the anticancer effects of irisin on cell viability of both LNCaP and DU-145 cell lines and also on the expression of MMP2 and MMP9 genes occurred in a dose- and time-dependent manner.

show abstract

Immunostaining characteristics of irisin in benign and malignant renal cancers

Cited by 20 publications

References 31 publications

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

Pathophysiological role of endogenous irisin against tumorigenesis and metastasis: Is it a potential biomarker and therapeutic?

The Effect of Irisin on Proliferation, Apoptosis, and Expression of Metastasis Markers in Prostate Cancer Cell Lines

Contact Info

Product

Resources

About